This study looks at how safe and effective two drugs, avutometinib (VS-6766) and defactinib (VS-6063), are for patients with a type of cancer called Low-Grade Serous Ovarian Cancer (LGSOC) that has come back after treatment. These drugs are kinase inhibitors, which help stop cancer cells from growing. The study compares this combination with other treatments chosen by doctors, to see which helps patients live longer without the cancer getting worse. This is a Phase 3 study, which means it’s in the last stage before a drug might get approved. Patients in the study will either receive the new drug combination or one of the five standard treatments. If the standard treatment doesn’t work, they might switch to the new combination.

• The study involves regular visits and follow-ups.
• Participants must be willing to use birth control if they can have children.
• The drugs are not yet approved by the U.S. Food and Drug Administration (FDA).